Physician profile

Mark J Ivey

Pulmonary Disease · Spring Lake, MI

NPI 1962450981

$1,534.07

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$99.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $481.70 2019-2021
Grifols USA, LLC $345.67 2019-2023 Prolastin-C Liquid
Harmony Biosciences LLC $207.94 2021-2024 Wakix
Zoll Respicardia, INC. $153.84 2019-2023 Remede System
Grifols Shared Services North America, INC. $140.77 2019-2022
Jazz Pharmaceuticals INC. $125.30 2019-2022
Eisai INC. $42.82 2020-2021
Shire North American Group INC $18.20 2019
Mylan Specialty L.P. $17.83 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark J Ivey

$1,534.07

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/361229/mark-j-ivey

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.